Brokerage firm Citigroup Maintains its rating on PRA Health Sciences Inc(NASDAQ:PRAH). In a research note issued to the investors, the brokerage major Raises the price-target to $66.00 per share. The shares have been rated Buy. The rating by Citigroup was issued on Sep 23, 2016.
In a different note, On Sep 22, 2016, Citigroup said it Maintains its rating on PRA Health Sciences Inc. In the research note, the firm Raises the price-target to $55.00 per share. The shares have been rated ‘Buy’ by the firm. On Sep 6, 2016, UBS said it Downgrades its rating on PRA Health Sciences Inc. In the research note, the firm Raises the price-target to $50.00 per share. The shares have been rated ‘Neutral’ by the firm. On Aug 1, 2016, Citigroup said it Maintains its rating on PRA Health Sciences Inc. In the research note, the firm Raises the price-target to $53.00 per share. The shares have been rated ‘Buy’ by the firm.
PRA Health Sciences Inc (PRAH) made into the market gainers list on Tuesdays trading session with the shares advancing 1.15% or 0.64 points. Due to strong positive momentum, the stock ended at $56.06, which is also near the day’s high of $56.07. The stock began the session at $55.4 and the volume stood at 3,12,743 shares. The 52-week high of the shares is $56.44 and the 52 week low is $33. The company has a current market capitalization of $3,416 M and it has 6,09,34,373 shares in outstanding.
PRA Health Sciences Inc(PRAH) last announced its earnings results on Jul 28, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $394.25M. Analysts had an estimated revenue of $381.25M. Earnings per share were $0.63. Analysts had estimated an EPS of $0.59.
Several Insider Transactions has been reported to the SEC. On Aug 22, 2016, Colin Shannon (President & CEO) sold 113,133 shares at $51.58 per share price.Also, On Aug 17, 2016, Linda Baddour (Executive VP & CFO) sold 69,380 shares at $52.00 per share price.On Aug 15, 2016, David W Dockhorn (Executive VP & CCO) sold 107,257 shares at $49.00 per share price, according to the Form-4 filing with the securities and exchange commission.
PRA Health Sciences Inc. is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. It offers therapeutic services in areas of pharmaceutical development including oncology central nervous system inflammation and infectious diseases. The Company performs an array of services across the spectrum of clinical development programs from the filing of investigational new drug (INDs) and similar regulatory applications to conducting all phases of clinical trials. Its service offerings include Product Registration Services which includes Phase IIb through III product registration trials and Phase IV trials inclusive of post-marketing commitments and registries; Strategic Solutions which provides Embedded Solutions and functional outsourcing services and Early Development Services which includes Phase I through Phase IIa clinical trials and bioanalytical laboratory services.